Quarter 2025 Earnings Conference Call. My name is Danielle, and I'll be your coordinator today. At this time, all participants are in a listen-only mode. As a reminder, the conference is being recorded for replay purposes. Also, we ask you to refrain from using cell phones, speakerphones or headsets during the Q&A portion of today's call. I would now like to turn the conference over to Christine Jewell, Head of Investor Relations. Please go ahead.

Thank you, and good morning. Welcome to Genworth's first quarter 2025 earnings call. The slide presentation that accompanies this call is available on the Investor Relations section of the Genworth website, investor.genworth.com. Our earnings release and financial supplement can also be found there, and we encourage you to review these materials. Speaking today will be Tom McInerney, President and Chief Executive Officer and Jerome Upton, Chief Financial Officer. Following our prepared remarks, we will open the call up for a question-and-answer period. In addition to our speakers, Jamala Arland, President and CEO of our U.S. Life insurance business, Kelly Saltzgaber, Chief Investment Officer; and Samir Shah, CEO of CareScout Services, will also be available to take your questions. During the call this morning, we may make various forward-looking statements. Our actual results may differ materially from such statements. We advise you to read the cautionary notes regarding forward-looking statements in our earnings release and related presentation, as well as the risk factors of our most recent annual report on Form 10-K as filed with the SEC. This morning's discussion also includes non-GAAP financial measures that we believe may be meaningful to investors. In our Investor Materials, non-GAAP measures have been reconciled to GAAP where required in accordance with SEC rules. Also, references to statutory results are estimates due to the timing of the filing of the statutory statements. And now, I'll turn the call over to our President and CEO, Tom McInerney.

Thank you, Christine. Good morning, everyone, and thank you for joining January's earnings call for the first quarter. Before I dive into our first quarter performance, I want to give a special welcome to Christine Jewell, who recently took over as Genworth's Head of Investor Relations. Christine has been at Genworth since 2009, most recently serving as Senior Director of Financial Planning and Analysis for our U.S. Life insurance companies. We are excited to have Christine in this new role. I would like to thank Brian Johnson for serving in this position for the past several quarters. Brian will be focusing on his existing roles as Vice President of Financial Planning and Analysis of Genworth and as Finance Leader of CareScout Services. I'm also pleased to welcome Morris Taylor to Genworth, who joined us on April 7 as our new Senior Vice President and Chief Information Officer. With his proven experience executing long-term visions for large technology organizations, Morris will lead our efforts to deliver a technology-enabled and human-centered experience for our customers, an important component of our CareScout growth strategy. Turning to our first quarter results, Genworth reported net income of $54 million or $0.13 per share. First quarter adjusted operating income was $51 million led by Enact, which had another excellent quarter and contributed $137 million in adjusted operating income to Genworth. The total estimated pre-tax statutory loss for our U.S. Life insurance companies was $1 million driven by losses in life and annuities, which were mostly offset by long-term care insurance. Jerome will discuss the financial results in more detail. Our liquidity remains strong, with Genworth ending the first quarter with cash and liquid assets of $211 million. We continue to execute well against Genworth's three strategic priorities. First, we increased shareholder value through Enact growing market value and consistent capital returns. Since its IPO in 2021, our mortgage insurance subsidiary has returned approximately $980 million to Genworth, serving as a reliable and essential source of free cash flow. Enact also yesterday announced a 14% increase to its quarterly dividend and a new $350 million share repurchase authorization. We remain very pleased with our approximately 81% ownership stake in Enact, which helps fuel Genworth's share repurchase program and growth investments in CareScout. Furthermore, as of April 16, Enact was added to the S&P Small Cap 600 Index, an important milestone that underscores its strong performance and positioning during its early years as a public company. We continued executing on our share repurchase program in the first quarter. Then we bought back $55 million worth of shares year to date through April, and since the program's initial authorization, we purchased a total of $600 million worth of shares at an average price of $5.75 per share. Second, we continue to maintain the self-sustainability of our customer-centric legacy LTC, life and annuity businesses. In the first quarter, we achieved $24 million of gross incremental premium approvals through our multi-year rate action program or MYRAP, with an average percentage increase of 28%. Since the program's inception in 2012, the MYRAP has been proven to be the single most effective lever for maintaining self-sustainability, generating a total of $31.3 billion in net present value. We anticipate that in-force rate approval this year will be smaller than in 2024, consistent with our long-term MYRAP plans. Turning to our third strategic priority, we are seeing strong growth at CareScout. CareScout has achieved dramatic growth in the number of matches between Genworth policyholders and CareScout quality network providers. During the first quarter of 2025, the number of matches increased to 576 compared to 52 in the first quarter of 2024, more than a 10x increase year over year as you'll see on Slide 67. We expect continued strong growth in the number of matches between CareScout providers and Genworth policyholders. Our provider network continues to strengthen its coverage and maintain its competitive pricing. Approximately 90% of CareScout's quality network for CQN providers have agreed to negotiated rates below the local cost of care and up to 20% lower than their standard rates. With home care costs exceeding $5,000 per month, this translates to monthly discounts of approximately $1,000 per month. Providers receive a fee equal to 25% of the monthly discount, and the remaining 75% of the discount is a reduction to Genworth's LTC claim cost. In some instances, the revenue for CareScout and Genworth's claim savings can be lower than the respective 25% and 75% levels if a policy's maximum benefit amount has been reached. We continue to expand the CareScout quality network. The network now includes nearly 550 high-quality person-centered home care providers nationwide and has grown to a 90% coverage level for the aged 65-plus census population in the United States. This represents 3 times growth in the network size year-over-year. We have begun discussions with several national assisted living communities on adding them to the network so we can serve a wider range of care needs. Notably, we're seeing growing interest from providers who initially declined to join the network, a clear signal that the CQN is gaining traction and credibility in the provider marketplace. As network size and awareness grows, we anticipate a greater portion of our LTC claimants will choose credentialed providers from our network for their care, helping them optimize each dollar of benefits and driving an estimated $1 billion to $1.5 billion in claims savings to Genworth over time. We are also executing on our plan to expand network access for other LTC insurance carriers with closed LTC blocks of business, providing a large potential new source of revenue for CareScout Services. We've already begun pilot programs with two leading insurers and continue to have productive discussions with several other national carriers about using the network. We made excellent progress towards bringing our new lower-risk individual CareScout insurance product to market and recently received product approval from the insurance compact, which includes 23 individual states. In addition to these approvals representing 23 states, we advanced product filings in eight additional jurisdictions. We remain on track to reenter the market in the second half of 2025. Our goal is to obtain approvals from a critical mass of 30 to 35 states before launching the product later this year. We are also in the process of developing a hybrid LTC product, which will combine cash value accumulation using equity index funds with a minimum guaranteed LTC benefit in addition to our holistic suite of long-term care resources, including the CQN. The expected demand for these new innovative CareScout LTC products underscores the market need for responsible, scalable solutions to help Americans face rising long-term care costs. We are also encouraged by the recent reintroduction of the Wish Act bipartisan bill co-sponsored by representatives Tom of New York and John Mulier of Michigan. This legislation would establish a public-private framework to provide financial support for individuals requiring long-term care while also strengthening the private market by encouraging broader access to insurance solutions. Genworth will continue to actively engage with policymakers to support constructive proposals, and we are encouraged by the increasing policy momentum aimed at addressing the nation's long-term care financing gap. Next, I want to provide an update on the litigation between AXA and Santander that we have previously referenced. The trial for the liability aspect of the case took place in London in March and concluded on April 10. We are now waiting for the judge to issue a ruling on liability, which is expected to occur sometime in mid- to late summer. A separate hearing on any damage amounts to be awarded will take place in December. Genworth has always believed AXA has a very strong case on the merits, and our side feels good about how the trial went. However, as we all know, litigation outcomes are impossible to predict, and we'll have no further comments on this litigation until the judge makes a liability ruling. During the first quarter, we also took actions to strengthen the alignment of our interests with AXA to seek the highest litigation recovery possible by agreeing to potentially cover up to GBP 80 million of access losses in this matter. In installments over the next 1.5 years, depending on developments in the case. We believe that proceeds resulting from this case will exceed any amounts that we may be required to pay to AXA under this arrangement. Before I conclude, I want to take a moment to discuss the current macroeconomic environment. As many business leaders, Wall Street analysts, economists and others have said, we faced substantial volatility and uncertainty because of the pending tariff negotiations currently taking place across global markets. As a financial services company, Genworth and our subsidiaries are not directly impacted by tariffs. However, if the ultimate outcome of the global tariff negotiations significantly impacts the U.S. and global economies and equity and fixed income markets, this will have some impact on our businesses. Our 2025 base case assumes a low single-digit increase in U.S. GDP. However, we rigorously stress test our operating plans, including under recession scenarios. A moderate recession, if it happens, would have a negative impact on earnings, but it's quite manageable for Genworth. Genworth has a very low level of holding company debt of only $790 million, which provides significant financial flexibility for us even if we face a more severe recession scenario. Regardless of the short- to intermediate-term disruption in world markets, demand for agent care products and services is expected to rise significantly as the 70 million baby boomers begin to reach peak long-term care age, with the number of 80-year-old baby boomers expected to double in the next 20 years. This trend will continue regardless of the broader economic backdrop, along with the growing need for practical funding solutions as younger generations confront the high cost of caring for their parents. Offerings like the CareScout quality network help Americans stretch every dollar they spend on care, delivering both meaningful impact to our families and sustained value for Genworth. In closing, we are very pleased with our continued progress on Genworth's key value drivers, along with another quarter of strong performance from Enact. Looking forward, we're well-positioned to continue advancing these initiatives throughout the rest of 2025. With that, I'll turn the call over to Jerome for a more detailed discussion of our financial results.

Thank you, Tom, and good morning, everyone. In the first quarter, we continued to build on our solid foundation and financial flexibility and deliver on our strategic priorities. Enact once again drove operating performance and continues to operate from a strong capital and liquidity position. We also continued to advance our multi-year rate action plan, made significant progress expanding CareScout and return capital to shareholders through our share repurchase program. I'll start with an overview of our financial performance and drivers, then provide an update on our investment portfolio and holding company liquidity before we open the call for Q&A. As shown on Slide 7, first quarter adjusted operating income was $51 million, driven by Enact. Our Long-Term Care Insurance segment reported an adjusted operating loss of $30 million, driven by lower limited partnership income and the anticipated decline in premiums from the impact of benefit reduction elections. This was partially offset by a liability remeasurement gain related to the actual variances from expected experience or A to E, primarily driven by seasonally high mortality. As we said last quarter, since the implementation of LDTI in 2023, we have seen an average quarterly loss from the A to E of about $65 million and continue to expect that we could see losses at this average level throughout 2025. As a reminder, quarterly fluctuations in U.S. GAAP results do not impact our cash flows, economic value or how we're managing the business. Life and Annuities reported an adjusted operating loss of $33 million in the first quarter. This included an adjusted operating loss of $44 million in life insurance, reflecting the unfavorable impacts of seasonally high mortality, partially offset by adjusted operating income of $11 million from annuities. In Corporate and Other, we reported a $23 million loss for the first quarter. The improvement versus the prior year loss of $38 million was driven by unfavorable tax timing of $15 million in the first quarter of 2024 that reversed by the end of the year and did not recur. Now taking a closer look at Enact's first quarter performance on Slide 8. Enact delivered $137 million in adjusted operating income in line with the prior quarter and up slightly versus the prior year, reflecting ongoing strong business performance and continued reserve releases driven by favorable cure performance. Primary insurance in force grew 2% year-over-year to $268 billion, supported by new insurance written and continued elevated persistency. As shown on Slide 9, Enact's favorable $47 million pretax reserve release drove a loss ratio of 12%. Enact's estimated PMIER sufficiency ratio remains strong at 165% or approximately $2 billion above requirements. Genworth's share of an Enact's book value, including AOCI, has increased to $4.2 billion at the end of the first quarter, up from $4.1 billion at year-end 2024, while at the same time, Enact has delivered significant capital returns to Genworth. Genworth received $76 million in capital returns from Enact in the first quarter. As Enact announced yesterday, it has increased its quarterly dividend by 14% and received Board approval for a new share repurchase authorization of $350 million. Genworth will participate in the share repurchase program in order to maintain its overall ownership at approximately 81%. Looking ahead, despite an uncertain macroeconomic backdrop, Enact continues to operate with solid business fundamentals, a strong balance sheet and is well-positioned to navigate through a range of potential market conditions. As a result, Enact continues to expect to return similar levels of capital to its shareholders in 2025 as it did in 2024. Turning to long-term care insurance starting on Slide 10. We are proactively managing LTC risk and maintaining the self-sustainability of the legacy LTC business. We continue to significantly reduce tail risk through our multi-year rate action plan, or MYRAP. As part of this effort, we're offering a suite of options to help policyholders manage premium increases while maintaining meaningful coverage and to enable us to reduce our exposure to certain higher-cost benefit features such as 5% compound inflation options and large lifetime benefit amounts. As of the end of the first quarter, we have achieved approximately $31.3 billion of in-force rate actions on a net present value basis. About 59% of policyholders presented with options have chosen to reduce benefits, helping to lower long-term risk. Notably, the exposure to individual LTC policies with the 5% compound inflation feature has decreased to approximately 36%, down from 57% in 2014. In addition to the MYRAP, we're reducing risk in innovative ways, including through the CareScout quality network and our LiveWell age well intervention program, which deliver value for policyholders while also driving claim savings over time. As we've said before, we are committed to managing the U.S. life insurance companies as a closed system leveraging their existing reserves and capital to cover future claims. We will not put capital into the legacy life insurance companies. And given the long-tail nature of our LTC insurance policies with peak claim years over a decade away, we do not expect capital returns from these companies. Slide 11 shows statutory pretax earnings for the U.S. life insurance companies with a loss of $1 million for the quarter. LTC income of $50 million included a benefit from seasonally high mortality, which typically trends lower through the remainder of the year. Earnings from in-force rate actions of $340 million were down from $462 million in the prior year, as the prior year included a significant benefit from the implementation of the LTC legal settlements, which are now materially complete. Life insurance had a loss of $34 million, driven by seasonally high mortality, and our annuity products reported a loss of $17 million, reflecting the net unfavorable impact of interest rate and equity market movements in the quarter. The consolidated risk-based capital ratio for Genworth Life Insurance Company, or GLIC, was an estimated 304% at the end of March compared to 306% at year-end 2024, reflecting the increase in required capital as we continue to grow our limited partnership portfolio. GLIC's consolidated balance sheet remains sound with capital and surplus of $3.5 billion as of the end of March. Our final statutory results will be available on our investor website with our first quarter filings later this month. Turning to Slide 12. Our investment portfolio remains resilient and is conservatively positioned to weather periods of market volatility, and we will continue to invest through the cycle. The majority of our assets are in investment-grade fixed maturities held to support our long-duration liabilities. New investable cash flows in our life insurance companies during the quarter, including alternatives, achieved yields of approximately 7%. Our alternative assets program is largely comprised of diversified private equity investments and has targeted returns of approximately 12%. There is potential to experience pressure around short-term performance, given the current market volatility. However, we are focused on investing for the long term, where we are confident that our track record of robust returns will prevail. We are committed to growing our alternative assets within regulatory limitations, as they remain a natural fit with long-tail liabilities. Next, turning to the holding company on Slide 13. We received $76 million in capital from Enact and ended the quarter with $211 million of cash and liquid assets. Included in our cash and liquid assets, we hold approximately $98 million of advanced cash payments from our subsidiaries for future obligations. This includes the remainder of our planned $75 million investment of capital in the new CareScout insurance company in 2025 to meet regulatory requirements, as we discussed last quarter. We do not consider this cash when evaluating holding company liquidity for the purpose of capital allocation or calculating the buffer to our debt service target. Our top capital allocation priorities, as shown on Slide 14, are to invest in long-term growth through CareScout, return cash to shareholders through our share repurchase program when our share price is below intrinsic value and opportunistically retire debt when attractive to us. We continue to expect to invest approximately $45 million to $50 million in CareScout services in total throughout 2025 as we continue to build out the platform. This investment will go towards adding new products, customers and foundation as we scale the business. Moving to shareholder returns. We repurchased $45 million of shares in the first quarter at an average price of $6.91 per share and another $10 million through the end of April. For the full year 2025, we continue to expect to allocate between $100 million to $120 million of share repurchases. This range may vary depending on business performance, market conditions and our share price. We're very pleased with the value created for shareholders through our share repurchase program. Our holding company debt stands at $790 million, and we are pleased with our financial flexibility given our liquidity level, sustainable cash flows from Enact and manageable debt level. In closing, we are delivering on our strategic priorities while proactively managing our liabilities and risks. As Tom said, we maintain the operational and financial flexibility to weather market volatility and uncertainty in today's macroeconomic environment. The multiyear rate action plan and additional risk mitigation strategies are ensuring the self-sustainability of the legacy LTC block, and we will continue to focus on delivering sustainable long-term growth through Enact and CareScout while returning meaningful value to shareholders through share repurchases and opportunistic debt retirement. Now, let's open up the line for questions.

And we'll take our first question from the line of Ryan Krueger with KBW. Please go ahead.

Good morning. Tom, I know you mentioned discussing the litigation, but my inquiry is more about the changes in the agreement with AXA. I just want to confirm my understanding. It seems like you are agreeing to cover up to $80 million in losses if they happen during the trial, but you would receive a larger amount of proceeds if they win. Is that accurate? If not, could you please clarify?

Thank you for the question, Ryan. AXA is a critical case for us due to the possibility of significant proceeds. To provide some context, AXA is seeking damages of around $700 million. Depending on the judge's ruling, this amount could include additional expenses and interest. Since we've covered most claims related to that figure, if it goes to trial or results in a settlement, there may be discrepancies in expectations. AXA anticipates recovering about GBP80 million, while we expect a much larger amount. Because they would prefer a lower final settlement, we aimed to align our interests during the trial in March. Our arrangement incentivizes both parties to seek the highest possible recovery. To facilitate this cooperation, we essentially guaranteed AXA's share based on the scenario where the bank would owe them something, although the exact amount is still uncertain. We believe AXA has a strong case, and typically, in similar situations, the selling entity, which is the bank here, ends up covering mis-selling costs. Given the magnitude, it was crucial for AXA and Genworth to collaborate effectively so that our interests could align.

Got it. That makes sense. And then I had a couple of questions on CareScout. One was just I know you're making a capital contribution to the new insurance entity this year to get it going, which I think you've already deducted from your holdco liquidity. Would you expect further capital contributions beyond this year to be needed for the insurance business? Or is it more just a start-up contribution?

So, Ryan, that's a great question. When you establish a new insurance company like CareScout Insurance, you are required to invest an initial amount of capital that exceeds what's required by RBC ratios. This is necessary as we anticipate that it will take about five years for the company to break even, although this period can vary. The early expenses associated with selling and commission are accounted for upfront, which results in a drag on statutory earnings initially. The $75 million represents the capital needed to address potential losses during these early years, calculated at a factor of five times the annual loss. This is a significant amount of capital. As we issue insurance policies, we'll incur those statutory expenses, necessitating RBC capital to support these costs. Over a period of about five to six years, we may need to inject additional capital, but this shouldn't be substantial. Additionally, all liabilities will be reinsured with A+ rated reinsurers, which mitigates capital usage since we receive seating commissions from them. We expect to recover about 40% to 50% of the reinsurance in the early years, allowing us to manage how much additional cash capital we need to provide. In summary, the initial capital is substantial due to regulatory demands, but we anticipate that as we grow and manage our reinsurance coverage, any future capital needs will be considerably lower—likely in the range of $20 million to $25 million over time, potentially a few times. Therefore, it is a capital-intensive start due to regulatory obligations.

Makes sense. And then just one more CareScout question, just one more on the CareScout quality network, maybe too early for this, but just I guess kind of wondering if you have like a rough time frame that you think that business, not the insurance business, but that business might get to a level that's closer to breakeven profitability?

I'll let Samir Shah, the CEO of that business, discuss its profitability and breakeven point. It's important to note that with 550 providers and 20% discounts, we are projecting future Genworth claim costs to save between $1 billion and $1.5 billion. We don't factor that into the breakeven analysis, but we've been funding the business expenses in the $35 million to $50 million range as we develop it. Even if breakeven is still some time away, we have effectively added value to the company of $1 billion to $1.5 billion based on how those discounts will reduce our claim costs. More importantly, what might interest you and other investors is the growth rate of the business and our expectations for it. So, I’ll ask Samir to share his insights on that.

Ryan, thank you for the question. As Tom alluded and as Jerome said before, given this is a new business, it will require some investments early on and take a couple of years to build out. But the early momentum has been really strong. The network is continuing to build that with great coverage, choice, and efficiency with the rate reductions we're able to do. And as we onboard assisted living communities and roll out new products, we think it will make it a more holistic offering for aging consumers all over. The adoption we're seeing from clients beyond January into other insurance companies and the pipeline we're building shows that the value proposition is not only clear, but it's necessary to solve what is becoming a bigger problem. And as you know, we've talked about 70 million direct-to-consumer clients, so the opportunity for us becomes quite significant. In terms of value and impact of Genworth, I think we deliver impact in three different ways. One is the savings, and we're on pace for the $1 billion to $1.5 billion in savings. And I think the savings alone allow CareScout services to be breakeven. But I think we bring in new revenue as we add new clients, both insurance and direct-to-consumer clients. And over the long run, we hope to add significant valuation for the company.

We'll take our next question from Brett Osetec with KBW. Please go ahead.

You guys mentioned the WISH act in your prepared remarks. Can you just elaborate a little bit more about what kind of tailwinds you think that might provide for the CareScout offering going forward?

Thank you, Brett, for your question. Our first product is a traditional long-term care insurance product that is fairly capped. Over the last 40 years, the average claims have been around $250,000. The most expensive claim we've processed was $3.4 million for a woman with Alzheimer’s who has been on claim for a long time and is still ongoing. By offering a maximum benefit of $250,000 in this new policy, we manage a significant portion of our tail risk. Initially, we offered unlimited benefits with high compound inflation, but $250,000 aligns with average claims historically. However, for severe cases like dementia or Alzheimer’s, claims tend to be much higher. For private insurers like CareScout, covering those high dementia-related claims necessitates higher premiums across all policies. We aim to keep the costs of this new product manageable for a wider range of consumers, likely around $3,000 to $3,500, depending on the individual’s choices, age, and medical history. We believe this pricing is appropriate for governments, as there's already a plan in Washington state for some level of coverage. The WISH Act, which Tom Quasi has introduced and reintroduced with bipartisan support, is primarily focused on catastrophic coverage, meaning individuals are responsible for initial costs based on their savings or private insurance, generally ranging between one to five years, depending on income. Our capitated coverage integrates well with that approach, and any costs exceeding that would be covered by the federal government. Since the federal and state governments often act as the payer of last resort for long-term care claims, including those under Medicaid, this strategy could relieve some future pressure on Medicaid. We are designing our products with the assumption that something like the WISH Act may eventually be enacted. The current challenge for Congress is ensuring that there is support for coverage, given that a significant majority of the 70 million baby boomers lack private long-term care coverage. With the high costs of care—average home care claims reaching around $75,000 and nursing homes costing approximately $127,000 for private rooms—finding a way to finance comprehensive catastrophic coverage remains a key concern. Right now, bipartisan support for new taxes to fund this is limited, so Congress will need to navigate that challenge as the baby boomers begin to age significantly, with many turning 80 this January. We are hopeful that states like California and New York will explore their own solutions, but ultimately, we believe that while private insurers won't cover the highest tail risk in long-term care, it can be a suitable area for the public sector to address. The critical question remains whether Congress and the administration are willing to fund this cost, which is significant but necessary.

It appears that there are no questions at this time. Ladies and gentlemen, I will now turn the conference back over to Mr. McInerney for closing comments.

Thank you very much, Danielle, and I want to thank everybody and Ryan and Brett for the great questions. And I want to thank you all for joining the call and for your ongoing support and interest in investments in Genworth. We're very proud of first quarter results, and Enact continues to do extremely well, and I assume many of you listen to their earnings call, and so they're in a good place. And I think we're making great progress on our three strategic priorities that Jerome and I outlined. So, we're looking forward to significant success in growing CareScout over time and also looking forward to continued good cash flow, strong cash flow from Enact. So, thank you very much. And Danielle, I'll turn it back over to you to close the call.

Ladies and gentlemen, this concludes Genworth Financial's First Quarter Conference Call. Thank you for your participation. At this time, the call ends.